The aim of this study is to test the hypothesis that addition of daily small dose of human menopausal gonadotropin (HMG) drug following oocytes retrieval could improve the fertility outcome in women undergoing in-vitro fertilization
The study will be conducted in the IVF unit of Cairo University. Females undergoing ICSI cycles in the age between 20 and 40 years will be allocated to one of 2 groups. Long agonist protocol will be used. Allocation to either one of 2 groups will be done on the day of oocytes retrieval. The first group will take (in addition to the routine care) daily human menopausal gonadotropin drug injection for 2 weeks. The second group will receive the routine care.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
600
Merional injections will be given to participants after ovum pickup in in-vitro fertilization cycles
Department of Obstetrics and Gynecology, Kasr Al-Ainy hospital
Cairo, Greater Cairo, Egypt
RECRUITINGLive birth rate
The live birth rate will be calculated by a statistician for each group
Time frame: This outcome will be calculated 2 years after enrollment of the first patient in the study
Clinical pregnancy rate
The clinical pregnancy rate will be calculated by a statistician for each group
Time frame: This outcome will be calculated 2 years after enrollment of the first patient in the study
Implantation rate
The implantation rate will be calculated by a statistician for each group
Time frame: This outcome will be calculated 2 years after enrollment of the first patient in the study
Miscarriage rate
The miscarriage rate will be calculated by a statistician for each group
Time frame: This outcome will be calculated 2 years after enrollment of the first patient in the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.